RTI-112

RTI-112.svg

RTI-112 is a chemical compound that belongs to the class of phenyltropanes. It is a potent dopamine reuptake inhibitor and has been studied for its potential use in the treatment of various medical conditions, including cocaine addiction and attention deficit hyperactivity disorder (ADHD).

Chemical Structure and Properties

RTI-112 is structurally related to other phenyltropanes, such as RTI-55 and RTI-113. The chemical structure of RTI-112 includes a tropane ring system with a phenyl group attached to the 3-position and a carboxylate ester at the 2-position. This structure is responsible for its high affinity for the dopamine transporter (DAT).

Mechanism of Action

RTI-112 functions primarily as a dopamine reuptake inhibitor. By binding to the dopamine transporter, it prevents the reabsorption of dopamine into the presynaptic neuron, thereby increasing the concentration of dopamine in the synaptic cleft. This action enhances dopaminergic neurotransmission, which is believed to contribute to its potential therapeutic effects.

Potential Therapeutic Uses

Cocaine Addiction

RTI-112 has been investigated as a potential treatment for cocaine addiction. Cocaine exerts its addictive effects by inhibiting the dopamine transporter, leading to increased dopamine levels in the brain. RTI-112, by similarly inhibiting the dopamine transporter, may help to reduce cocaine cravings and withdrawal symptoms.

Attention Deficit Hyperactivity Disorder (ADHD)

RTI-112 has also been studied for its potential use in treating attention deficit hyperactivity disorder (ADHD). ADHD is characterized by symptoms of inattention, hyperactivity, and impulsivity, which are thought to be related to dysregulation of dopaminergic and noradrenergic systems. By increasing dopamine levels, RTI-112 may help to alleviate these symptoms.

Side Effects and Risks

As with other dopamine reuptake inhibitors, RTI-112 may have side effects, including increased heart rate, elevated blood pressure, and potential for abuse. Long-term use of dopamine reuptake inhibitors can also lead to neuroadaptive changes in the brain, which may contribute to tolerance and dependence.

Research and Development

Research on RTI-112 is ongoing, with studies focusing on its pharmacological profile, therapeutic potential, and safety. Preclinical studies have shown promising results, but further research is needed to fully understand its efficacy and safety in humans.

See Also

• Dopamine reuptake inhibitor
• Phenyltropane
• RTI-55
• RTI-113
• Cocaine addiction
• Attention deficit hyperactivity disorder